Meta-analysis examines the effectiveness of interventions in improving and preventing diabetes depression.

Do you use Diabetes Apps with your patients? Follow the link to let us know and see what others are doing!

Type 2 patients who used saxagliptin or sitagliptin had similar risks for heart failure as those who received other anti-hyperglycemic agents, according to a retrospective cohort study.

Mrs. Wilson is an overweight 71-year old African American patient who has come to your clinic today for a new patient visit. She recently moved to the area to live with her daughter and is concerned about her diabetes care plan. She was diagnosed with type 2 diabetes 12 years ago at a wellness check through routine screening. In hindsight, she wonders if maybe she “went undiagnosed for a while” because she “didn’t get to the clinic very often and was having some problems with frequent urination at night” before she was screened. She currently takes metformin, glyburide, captopril, pravastatin, aspirin and has recently titrated to.6 U/kg/day insulin NPH as a nightly basal dose. Her current A1C goal is below 7.5% and she has been working hard to get to that level. However, for the first time her life, she is finding herself to be nauseated and irritable in the morning, but always feels better after a little breakfast. She states she feels “pretty good for her age” although she occasionally has “a little chest tightness when walking more than 4 or 5 blocks.” Last time she remembered to check it a few days ago, her postprandial glucose was a little high at 214 mg/dL. After discussing her situation with her, you decide to modify Mrs. Wilson’s antihyperglycemic regimen. Which of the following treatment options would you choose? [A] metformin + long-acting analogue + rapid-acting analogue [B] metformin + glyburide + long-acting insulin analogue + rapid-acting analogue [C] metformin + glyburide + NPH + rapid-acting analogue [D] metformin + NPH + rapid-acting analogue Follow the link to see if you're correct!

According to more than 200 studies involving 1.4 million patients, metformin reduces heart disease risk in diabetes patients more effectively than its competitors.

A year after the FDA warning, a strong response to the question: are SGLT-2 inhibitors safe?

This is the fourth drug to treat diabetes that also can reduce the risk of heart disease.

A secondary analysis of the TECOS trial affirms sitagliptin does not increase heart failure risk for patients with type 2 diabetes.

According to a new study, one more disease is associated with diabetes: twin study suggests genetic link between obesity, psoriasis and diabetes.

Study shows effect low levels of the hormone have on blood glucose.